Snapshot from Jun 09, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / Tiziana Foralumab na-SPMS Clinical Data
Tech clinical trial data

Tiziana Foralumab na-SPMS Clinical Data

Analysis based on 6 articles · First reported May 19, 2026 · Last updated May 19, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive clinical data for Foralumab could lead to increased investor confidence in Tiziana Life Sciences, potentially boosting its stock price. This development also signals progress in the treatment of Secondary Progressive Multiple Sclerosis, which could impact the broader biotechnology and pharmaceutical industries.

Biotechnology Pharmaceuticals
Event Summary

Tiziana Life Sciences announced updated positive clinical data from its Expanded Access Program for intranasal Foralumab, its lead candidate for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The data, collected from March 2025 to March 2026, showed that Foralumab was well tolerated and demonstrated encouraging trends in stabilizing disability and improving fatigue in 14 patients. Specifically, 64% of patients achieved a clinically meaningful improvement in their Modified Fatigue Impact Scale (MFIS) score. While the small sample size means the results are not statistically significant and represent a trend analysis only, key figures like Howard L. Weiner and Ivor Elrifi expressed strong support for the drug's potential as a novel immunomodulatory therapy and its advancement towards approval.

Key Actions
100 Tiziana Life Sciences announced publication
90 Tiziana Life Sciences observed favorable trends
70 Howard L. Weiner commented on results
70 Ivor Elrifi expressed pleasure
Entities Involved
stock
Tiziana Life Sciences
Tiziana Life Sciences announced positive updated clinical data for its lead candidate, intranasal foralumab, in patients with non-active Secondary Progressive Multiple Sclerosis, which could significantly advance its drug development program and potential market position.
Importance 100 Sentiment 70
per
Howard L. Weiner
Howard L. Weiner, Director of the Ann Romney Center for Neurologic Diseases at Brigham and Women s Hospital and Chair of the Scientific Advisory Board of Tiziana Life Sciences, provided an encouraging statement supporting the potential of intranasal foralumab.
Importance 60 Sentiment 50
per
Ivor Elrifi
Ivor Elrifi, CEO of Tiziana Life Sciences, expressed satisfaction with the positive data and the company's intention to advance the program toward approval, highlighting the drug's potential as a new treatment paradigm.
Importance 60 Sentiment 50
oth
Ann Romney Center for Neurologic Diseases
The Ann Romney Center for Neurologic Diseases is affiliated with Howard L. Weiner, who commented on the clinical data, lending credibility to the findings.
Importance 20 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.